Myocardial disarray
Myocardial disarray refers to the abnormal arrangement of cardiac muscle fibers, which can be observed in certain pathological conditions. It is most commonly associated with hypertrophic cardiomyopathy (HCM), a genetic disorder characterized by the thickening of the heart muscle. Myocardial disarray is considered a hallmark histological feature of HCM and can contribute to the development of arrhythmias and sudden cardiac death.
Pathophysiology[edit]
In a healthy heart, cardiac muscle fibers are organized in a parallel fashion, allowing for efficient contraction and relaxation. In myocardial disarray, this orderly arrangement is disrupted, with fibers oriented in multiple directions. This disorganization can impair the mechanical function of the heart and create an arrhythmogenic substrate.
The exact mechanism leading to myocardial disarray is not fully understood, but it is believed to be related to genetic mutations affecting the sarcomere, the basic contractile unit of muscle fibers. Mutations in genes encoding sarcomeric proteins, such as myosin-binding protein C and beta-myosin heavy chain, are commonly implicated in HCM and the associated myocardial disarray.
Clinical Significance[edit]
Myocardial disarray is often asymptomatic and may only be discovered incidentally during histological examination of cardiac tissue. However, its presence is significant in the context of hypertrophic cardiomyopathy, where it is associated with an increased risk of ventricular arrhythmias and sudden cardiac death.
In patients with HCM, the degree of myocardial disarray can correlate with the severity of the disease and the risk of adverse outcomes. It is also a feature observed in other conditions, such as dilated cardiomyopathy and congenital heart defects, although it is less characteristic in these contexts.
Diagnosis[edit]
The diagnosis of myocardial disarray is primarily made through histopathological examination of cardiac tissue, typically obtained via biopsy or at autopsy. Under the microscope, myocardial disarray is identified by the presence of disorganized muscle fibers with varying orientations.
Advanced imaging techniques, such as cardiac magnetic resonance imaging (MRI), can also provide indirect evidence of myocardial disarray by detecting areas of fibrosis and abnormal myocardial architecture.
Management[edit]
There is no specific treatment for myocardial disarray itself. Management focuses on addressing the underlying condition, such as hypertrophic cardiomyopathy. This may include lifestyle modifications, pharmacological therapy (e.g., beta-blockers, calcium channel blockers), and in some cases, surgical interventions like septal myectomy or the implantation of a cardioverter-defibrillator to prevent sudden cardiac death.
Prognosis[edit]
The prognosis of individuals with myocardial disarray depends largely on the associated cardiac condition. In the context of hypertrophic cardiomyopathy, the presence of significant myocardial disarray can indicate a higher risk of complications, including arrhythmias and heart failure. Regular monitoring and appropriate management of the underlying condition are crucial to improving outcomes.
Research Directions[edit]
Ongoing research aims to better understand the genetic and molecular basis of myocardial disarray and its role in cardiac diseases. Advances in genetic testing and imaging techniques continue to enhance the ability to diagnose and manage conditions associated with myocardial disarray.
See Also[edit]
Cardiovascular disease A-Z
Most common cardiac diseases
- Cardiac arrhythmia
- Cardiogenetic disorders
- Cardiomegaly
- Cardiomyopathy
- Cardiopulmonary resuscitation
- Chronic rheumatic heart diseases
- Congenital heart defects
- Heart neoplasia
- Ischemic heart diseases
- Pericardial disorders
- Syndromes affecting the heart
- Valvular heart disease
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
A[edit]
- Accelerated idioventricular rhythm
- Acute decompensated heart failure
- Arteriosclerotic heart disease
- Athletic heart syndrome
- Atrial flutter
- Atrioventricular fistula
- Cardiovascular disease in Australia
- Autoimmune heart disease
B[edit]
C[edit]
- Ebb Cade
- Cardiac allograft vasculopathy
- Cardiac amyloidosis
- Cardiac asthma
- Cardiac tamponade
- Cardiogenic shock
- Cardiogeriatrics
- Cardiorenal syndrome
- Cardiotoxicity
- Carditis
- Coronary artery aneurysm
- Coronary artery anomaly
- Coronary artery disease
- Spontaneous coronary artery dissection
- Coronary artery ectasia
- Coronary occlusion
- Coronary steal
- Coronary thrombosis
- Coronary vasospasm
- Cœur en sabot
- Coxsackievirus-induced cardiomyopathy
D[edit]
E[edit]
H[edit]
- Heart attack
- Heart failure
- Heart failure with preserved ejection fraction
- Heart to Heart (1949 film)
- High-output heart failure
- Hyperdynamic precordium
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
I[edit]
- Idiopathic giant-cell myocarditis
- Interventricular dyssynchrony
- Intraventricular dyssynchrony
- Isolated atrial amyloidosis
K[edit]
L[edit]
M[edit]
- Mydicar
- Myocardial bridge
- Myocardial disarray
- Myocardial rupture
- Myocardial scarring
- Myocardial stunning
- Myocarditis
N[edit]
O[edit]
P[edit]
- Papillary fibroelastoma
- Pathophysiology of heart failure
- Postpericardiotomy syndrome
- Pulmonary vein stenosis
R[edit]
S[edit]
- Saturated fat and cardiovascular disease
- SCAR-Fc
- Shone's syndrome
- Strain pattern
- Subacute bacterial endocarditis
- Sudden cardiac death of athletes
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
T[edit]
V[edit]
W[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian